Aurinia Pharmaceuticals (AUPH) Earnings Analysis
Aurinia Pharmaceuticals (AUPH) next reports earnings on 2026-07-30, consensus EPS 0.19 USD. Last quarter (2026-05-07) it beat with EPS 0.25 USD vs 0.18 USD est (+38.9%). It has beaten estimates in 6/7 recent quarters (86%). Trailing P/E 6.84.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AUPH next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 0.19 USD |
| Revenue estimate | 0.08B |
AUPH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.25 USD | 0.18 USD | +38.9% | Beat |
| 2026-02-26 | 0.26 USD | 0.21 USD | +23.8% | Beat |
| 2025-07-31 | 0.16 USD | 0.17 USD | -5.9% | Miss |
| 2025-05-12 | 0.16 USD | 0.08 USD | +100% | Beat |
| 2025-02-27 | 0.09 USD | 0.03 USD | +200% | Beat |
| 2024-11-07 | 0.1 USD | 0.02 USD | +400% | Beat |
| 2024-08-01 | 0.02 USD | 0.01 USD | +100% | Beat |
Beat rate: 6/7 (86%) over reported quarters with consensus data.
AUPH valuation and analyst view
| Trailing P/E | 6.84 |
|---|---|
| Trailing EPS | 2.253 USD |
| Price / book | 3.58 |
| Dividend yield | 0.00% |
| Market cap | 1.97B |
| Analyst consensus | Buy (11 buy / 4 hold / 0 sell) |
| Avg price target | 15.5 USD |
Related research pages
Frequently asked questions
When is Aurinia Pharmaceuticals (AUPH)'s next earnings date?
Aurinia Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.19 USD and revenue estimate of 0.08B.
Did AUPH beat earnings last quarter?
In its 2026-05-07 report, AUPH posted EPS of 0.25 USD versus a 0.18 USD estimate — a beat of 38.9%.
What is AUPH's earnings track record?
Over the last 7 reported quarters with consensus data, AUPH beat estimates 6 times (86%).
What is AUPH's current P/E ratio and EPS?
AUPH trades at a trailing P/E of 6.84 on trailing EPS of 2.2527894239848916 USD.
What do analysts rate AUPH?
Analyst consensus is "Buy" across 15 ratings (0 strong buy, 11 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 15.5 USD.